Myocardial regeneration strategy using wharton's jelly multipotent stem cells as an 'unlimited' therapeutic agent: 3-year outcomes in a pilot cohort of circulate-acute myocardial infarction trial.
Event: ESC Congress 2018
Topic: Treatment, Other
Session: Pharmacologic treatment of acute coronary syndromes
